Back to today’s briefing

Story perspectives

Biogen's Revenue Soars 6% with New Treatments

5/2/2025

22 4

Summary

Story summary

Biogen celebrated a robust 6% revenue surge in Q1 2025, raking in $2.4 billion, fueled by the successful launches of innovative treatments like Leqembi for Alzheimer's, Zurzuvae for postpartum depression, and Skyclarys for Friedreich’s ataxia. CEO Chris Viehbacher highlighted a pivotal transformation, with nearly half of the revenue now stemming from diverse, non-MS products.

1 of 1

Story summary

Biogen celebrated a robust 6% revenue surge in Q1 2025, raking in $2.4 billion, fueled by the successful launches of innovative treatments like Leqembi for Alzheimer's, Zurzuvae for postpartum depression, and Skyclarys for Friedreich’s ataxia. CEO Chris Viehbacher highlighted a pivotal transformation, with nearly half of the revenue now stemming from diverse, non-MS products.